Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative therapies for serious muscle diseases. Founded in 2017, Dyne has quickly established itself in the biopharmaceutical industry, particularly in the realm of gene therapy and muscle-targeted drug development.
The company’s core offerings include its proprietary FORCE™ platform, which enables the creation of targeted therapies that address the underlying causes of muscle disorders. This unique approach positions Dyne Therapeutics as a leader in the market, with a commitment to transforming the lives of patients suffering from debilitating conditions.
With significant advancements in its research and development pipeline, Dyne Therapeutics continues to make notable strides, solidifying its reputation as a key player in the biotechnology sector.
-22 vs industry average
Dyne Therapeutics, Inc.’s score of 18 is lower than 16% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Dyne Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Dyne Therapeutics, Inc. yet.
Dyne Therapeutics, Inc.'s reported carbon emissions
Dyne Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Dyne Therapeutics may still be in the early stages of developing a comprehensive climate strategy or reporting framework.
As the biopharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Dyne Therapeutics to establish clear climate commitments and reduction initiatives. This could include setting science-based targets for emissions reductions, engaging in renewable energy initiatives, or participating in industry-wide climate pledges. Without such commitments, the company may face challenges in aligning with broader environmental goals and expectations from stakeholders.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Dyne Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Dyne Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Dyne Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project